A. Eggermont

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.

A. Eggermont, C. Punt, P. Patel, 2006, European journal of cancer.

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

A. Enk, D. Schadendorf, R. Dummer, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidemiology of invasive cutaneous melanoma

A. Hauschild, A. Eggermont, R. MacKie, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Reasons for failure to identify positive sentinel nodes in breast cancer patients with significant nodal involvement.

A. Y. de Kanter, C. V. van Eijck, A. V. van Geel, 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.

A. Eggermont, V. Cocquyt, P. Patel, 2011, European journal of cancer.